Xtx Topco LTD Cytom X Therapeutics, Inc. Transaction History

Xtx Topco LTD

$1.3 Billion
Q3 2024

A detailed history of Xtx Topco LTD transactions in Cytom X Therapeutics, Inc. stock. As of the latest transaction made, Xtx Topco LTD holds 43,664 shares of CTMX stock, worth $46,720. This represents 0.0% of its overall portfolio holdings.

Number of Shares

43,664

Previous 60,586 27.93%

Holding current value

$46,720

Previous $73,000 30.14%

% of portfolio

0.0%

Previous 0.01%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$1.12 - $1.51 $18,952 - $25,552	-16,922 Reduced 27.93%	43,664 $51,000
Q2 2024 Aug 12, 2024	BUY	$1.21 - $5.13 $58,119 - $246,409	48,033 Added 382.64%	60,586 $73,000
Q1 2024 May 13, 2024	SELL	$1.41 - $2.74 $10,885 - $21,152	-7,720 Reduced 38.08%	12,553 $27,000
Q4 2023 Feb 13, 2024	BUY	$1.07 - $1.55 $21,692 - $31,423	20,273 New	20,273 $31,000
Q1 2023 May 12, 2023	SELL	$1.48 - $2.88 $17,407 - $33,874	-11,762 Reduced 39.77%	17,815 $26,000
Q4 2022 Feb 14, 2023	SELL	$1.19 - $1.91 $18,172 - $29,167	-15,271 Reduced 34.05%	29,577 $47,000
Q3 2022 Nov 14, 2022	SELL	$1.23 - $1.97 $68,579 - $109,839	-55,756 Reduced 55.42%	44,848 $65,000
Q2 2022 Aug 15, 2022	SELL	$1.53 - $2.89 $27,134 - $51,254	-17,735 Reduced 14.99%	100,604 $184,000
Q1 2022 May 13, 2022	BUY	$2.67 - $4.68 $288,824 - $506,254	108,174 Added 1064.18%	118,339 $316,000
Q4 2021 Feb 11, 2022	BUY	$3.87 - $7.39 $39,338 - $75,119	10,165 New	10,165 $44,000
Q3 2021 Nov 12, 2021	SELL	$4.32 - $6.43 $92,543 - $137,743	-21,422 Closed	0 $0
Q2 2021 Aug 12, 2021	BUY	$6.33 - $9.91 $135,601 - $212,292	21,422 New	21,422 $136,000

Others Institutions Holding CTMX

# of Institutions

Shares Held

50.7M

Call Options Held

112K

Put Options Held

8.3K

View Full List

About CytomX Therapeutics, Inc.

Ticker CTMX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 65,950,200
Market Cap $70.6M
Description
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical...

More about CTMX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Xtx Topco LTD, based on Form 13F filings with the SEC.

News

Stay updated on Xtx Topco LTD with notifications on news.

Account